Monoamine oxidase inhibitors
GPTKB entity
Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:affects |
increase in dopamine levels
increase in norepinephrine levels increase in serotonin levels |
| gptkbp:availability |
generic and brand names
|
| gptkbp:class |
MAOIs
|
| gptkbp:contraindication |
certain medications
certain foods high in tyramine |
| gptkbp:discovery |
by researchers in the 1950s
|
| gptkbp:example |
gptkb:Isocarboxazid
gptkb:Phenelzine gptkb:Selegiline gptkb:Tranylcypromine |
| gptkbp:first_introduced |
1950s
|
| https://www.w3.org/2000/01/rdf-schema#label |
Monoamine oxidase inhibitors
|
| gptkbp:interacts_with |
antidepressants
opioids stimulants serotonin syndrome |
| gptkbp:mechanism_of_action |
inhibition of monoamine oxidase enzyme
|
| gptkbp:notable_for |
in attention deficit hyperactivity disorder
in atypical depression in binge eating disorder in bulimia nervosa in chronic fatigue syndrome in chronic pain management in fibromyalgia in migraine prevention in obsessive-compulsive disorder in panic disorder in post-traumatic stress disorder in seasonal affective disorder in social anxiety disorder in treatment-resistant depression |
| gptkbp:regulatory_compliance |
prescription medication
|
| gptkbp:research |
ongoing studies on efficacy
|
| gptkbp:side_effect |
dizziness
dry mouth weight gain hypertensive crisis |
| gptkbp:targets |
neurotransmitters
|
| gptkbp:used_for |
treatment of anxiety disorders
treatment of depression |
| gptkbp:bfsParent |
gptkb:Atomoxetine
gptkb:Claritin-D gptkb:Allegra-D |
| gptkbp:bfsLayer |
6
|